Patient-reported adherence to coprescribed proton pump inhibitor gastroprotection in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis patients using nonsteroidal anti-inflammatory drugs by Henriksson K et al.
© 2014 Henriksson et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Patient Preference and Adherence 2014:8 1611–1617
Patient Preference and Adherence Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1611
OriginAl reseArch
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/PPA.S70651
Patient-reported adherence to coprescribed 
proton pump inhibitor gastroprotection 
in osteoarthritis, rheumatoid arthritis, and 
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Background: Patients with osteoarthritis (OA), rheumatoid arthritis (RA), or ankylosing 
spondylitis (AS) are commonly treated with nonsteroidal anti-inflammatory drugs (NSAIDs), 
sometimes with a concomitant gastroprotective proton pump inhibitor (PPI). The present study 
examines real-life patient adherence to PPIs when coprescribed with NSAIDs. 
Methods: This retrospective medical record survey identified patients diagnosed with OA, RA, 
or AS who had PPIs coprescribed with NSAIDs for prevention of NSAID-associated gastroin-
testinal ulcers. Actual NSAID and PPI intake was retrospectively recorded using a self-reported 
questionnaire. Adherence to PPI treatment was assessed using descriptive statistics. 
Results: In total, 96 patients (69% female, mean age 67 years, 72% OA, 16% RA, 12% AS) 
were included. The mean patient-reported adherence to coprescribed PPIs was 73%–81%. The 
percentage of patients with a self-reported adherence of 80% was 26%. No predictive factors 
for low adherence could be identified.
Conclusion: Despite doctors’ instructions to use PPIs concomitantly with NSAIDs, the mean 
patient-reported adherence to coprescribed PPIs in this population indicates a risk of a “gastro-
protective treatment gap”. The patients’ adherence to gastroprotective PPIs for the prevention 
of NSAID-associated upper gastrointestinal ulcers can be improved. 
Keywords: patient adherence, proton pump inhibitors, nonsteroidal anti-inflammatory drugs, 
gastroprotection, osteoarthritis, self-reported questionnaires
Introduction
Patient adherence to medication is necessary if clinical treatment regimens are to be 
successful and associated with positive patient outcomes.1–3 However, poor patient 
adherence to prescribed treatments is a common issue, seen almost independently 
of the therapeutic area. In patients with arthritis, adherence ranges from 55% to over 
80% depending on the drug studied.4
Nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin and selective 
cyclooxygenase-2 inhibitors, are a widely used treatment in arthritis.5,6 Adverse events, 
for example, gastrointestinal events like peptic ulcers, are the main concern of NSAID 
treatment.7–11 These may also lead to disruption of NSAID treatment, potentially reduc-
ing both positive clinical outcomes and elevating health care costs.12
There is strong evidence that the risk of ulcers and bleeding in the upper, but not 
lower, gastrointestinal tract may be decreased by concomitant therapy with proton 
correspondence: Kenneth henriksson
reuma city, Klara södra Kyrkogata 20, 
se-111 52 stockholm, sweden
Tel +46 823 9910
Fax +46 820 1134
email kenneth.henriksson@ownit.nu 
Journal name: Patient Preference and Adherence
Article Designation: Original Research
Year: 2014
Volume: 8
Running head verso: Henriksson et al
Running head recto: Real-life adherence to PPIs coprescribed with NSAIDs
DOI: http://dx.doi.org/10.2147/PPA.S70651Patient Preference and Adherence 2014:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1612
henriksson et al
pump inhibitors (PPIs).13 Concomitant gastroprotective 
treatment with a PPI is also recommended in guidelines as 
a therapy to lower the risk of NSAID-induced gastrointes-
tinal side effects.14,15 Adherence to PPI therapy is important 
in NSAID-treated patients, and the “gastroprotection gap”, 
such as low utilization of gastroprotective strategies and low 
adherence to gastroprotection among users of NSAIDs at high 
risk of adverse gastrointestinal events,16,17 increases the risk 
of gastrointestinal events, death, and health care costs.12,18–20 
Knowledge of real-life patient adherence to PPIs in NSAID-
treated patients is lacking. 
This study specifically focused on measuring self-
reported adherence to PPIs over a 7-day period in patients 
with osteoarthritis (OA), rheumatoid arthritis (RA), or anky-
losing spondylitis (AS) linked to their intake of coprescribed 
NSAID treatment.
Patients and methods
study design and objectives
This was a retrospective, cross-sectional, observational 
study to assess patient-reported adherence to PPI treat-
ment when coprescribed NSAID treatment (Anatomical 
Therapeutic Chemical Classification M01A, except M01AH 
and M01AX) for the prevention of upper gastrointestinal 
side effects associated with NSAID treatment in patients 
with OA, RA, or AS in Sweden. Patients should have been 
instructed by their physician to take a PPI on every day of 
NSAID intake. The study was approved by the regional 
ethical review board of Stockholm (DNR 2011/2118-31/3) 
and registered at ClinicalTrials.gov (NCT01519375). The 
study was conducted in accordance with the principles stated 
in the Declaration of Helsinki. 
Patient population
Male and female patients, 18 years of age, with a diagnosis 
of OA, RA, or AS were consecutively identified from medical 
records. The patients were required to have current prescrip-
tions of oral NSAID treatment and PPIs for the prevention 
of NSAID-associated gastrointestinal ulcers, with a doctor’s 
instruction to use the drugs on the same day. Patients were 
excluded if they were participating in any other trial involving 
a PPI or an NSAID, had been prescribed a PPI as an acute 
treatment for gastrointestinal events or symptoms (eg, gas-
trointestinal ulcer, dyspepsia, gastritis, or gastroesophageal 
reflux disease) within the last 8 weeks, if they reported taking 
NSAIDs on fewer than three of the reported days, or if they 
were unable to complete a study-specific patient self-reported 
questionnaire (SRQ). Seven primary care centers and one 
rheumatology center participated in the study. Diagnosis 
of OA, RA, or AS was according to the clinical practice 
at each participating center. Data were collected between 
March and May 2012.
study conduct
Patients who fulfilled the inclusion criteria submitted a signed 
informed consent form and a completed SRQ to the investi-
gators. Data on PPIs and NSAIDs were recorded in separate 
sections of the SRQ. The first question in each section asked 
patients about their general use of the drug. Patients were 
then asked to retrospectively specify their NSAID and PPI 
intake during the previous 7 days using “yes”, “no”, or “do 
not recall” for each specific day. The data were entered into 
a web-based case report form together with complementary 
information from patients’ medical records on disease char-
acteristics and prescribed medications.
Assessing adherence
The level of adherence to PPIs was assessed retrospectively 
over a 7-day period using the SRQ. The objective was to 
assess patient-reported adherence to PPI treatment on actual 
days of NSAID treatment and to assess the proportion of 
patients with reported adherence 80%. For the primary 
variable, adherence to PPI treatment was defined as the 
proportion of NSAID treatment days on which the patient 
also indicated taking a PPI. 
Adherence to the PPI was then calculated as the mean per-
centage of adherence in the total study population, assessed 
for all patients using two different methods. The first was a 
more conservative approach, where adherence was calculated 
using only the answers concerning PPI intake for the days 
where a definite “yes” or “no” for adherence was available. 
In the second and less conservative (sensitivity) approach, a 
day with non-reported PPI intake data or where the answer 
for PPI intake was “do not recall” was considered to be a 
day of PPI nonadherence, if NSAID intake on the same day 
was “yes”.
statistical analysis
All data were analyzed using descriptive statistics. Factors 
predictive of low adherence were tested using logistic regres-
sion. Data are presented using summary statistics.
Results
Patient demographics
In total, 74% (134/180) of the patients who received a ques-
tionnaire completed it. Of these, 96 patients (69% females, Patient Preference and Adherence 2014:8 submit your manuscript | www.dovepress.com
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mean age 67 years) fulfilled all inclusion criteria and were 
included in the final analyses. The majority of the excluded 
38 patients only reported taking NSAIDs less than 3 days per 
week. Seventy-two percent of the patients had a diagnosis of 
OA, 16% of RA, and 12% of AS; 39% and 22% had medical 
record histories of dyspepsia and gastroesophageal reflux 
disease, respectively.
Drugs prescribed
The three NSAIDs most commonly used by patients were 
diclofenac (34%), naproxen (24%), and ketoprofen (20%, 
Figure 1). The most common PPI was omeprazole, used by 
94% of patients.
Patient-reported adherence
Overall patient-reported adherence to coprescribed PPIs 
when taking NSAIDs (calculated as a mean percentage of 
all patients) was 81.1% (Figure 2A) and 73.4% (Figure 2B) 
using the conservative and less conservative approach, respec-
tively. The holistic interpretation of adherence data from six 
patients had an effect on the mean overall adherence in the 
less conservative (sensitivity) approach (Table 1), resulting in 
a marked and lowered adherence for the total population.
Overall, six patients reported “yes” on one day of PPI 
intake and then had missing data for the remaining 6 days. 
All responded “never take PPI” or “I refrain from taking PPI 
on at least 3 days a week” to the general question on PPI 
intake over a longer period of time. One patient reported a 
“no” on one day of PPI intake and then had missing data for 
the remaining 6 days, but the adherence did not change when 
analyzed using the less conservative approach.
Twenty-six percent of the patients had a self-reported 
adherence of 80%, calculated using the conservative 
approach (Figure 3). Adherence differences between high-
dose and low-dose NSAIDs, type of NSAID drug, sex, and 
diagnosis of OA, RA, or AS were tested, but no significant 
differences were detected. No factors predictive of low 
adherence could be identified.
Discussion
Few studies have assessed patient adherence to medication 
for the chronic treatment of nonmalignant pain.21–23 Here a 
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patient SRQ method was used to directly determine patient-
reported adherence to PPI treatment when coprescribed with 
NSAIDs to prevent upper gastrointestinal ulcers in patients 
with OA, RA, or AS. The patients all required treatment with 
gastroprotective agents based on physicians’ clinical judg-
ment and were instructed to always coadminister PPI with 
their NSAID treatment. Nevertheless, the patient-reported 
adherence in this study was between 73% (less conservative 
approach) and 81% (conservative approach). This corre-
sponds to PPI adherence rates previously reported in real life 
registry studies.24–27 An adherence below 80% indeed indi-
cates that there is a “gastroprotection gap” in approximately 
20%–30% of NSAID-treated OA, RA, and AS patients at risk 
of adverse upper gastrointestinal events, despite a physician’s 
instruction to coadminister the drugs.
Adherence is measured commonly as a percentage over 
a period of time using one or a combination of methods, and 
can be measured either directly or indirectly. Direct methods 
measure serum drug/drug metabolite levels, which reflect 
actual drug intake, but are costly and provide no feedback 
to the point of care.1,28 Indirect methods include pill counts, 
pharmacy dispensing records, refill adherence, medication 
event monitoring system, and patient self-reported data, such 
as SRQs.1,29 While indirect methods are more common and 
easier to use, they risk overestimation of adherence and do 
not necessarily measure drug intake. All methods have their 
limitations and there is no “gold standard”.1
SRQs are easy to use, cheap, measure adherence at 
source, and provide direct feedback. One disadvantage of 
the SRQ method is that it only provides an overall estimate 
of adherence over the specified time period.29 It may also 
be subject to “answering bias”, where only a selection of 
patients actually respond to the SRQ, and the adherence 
may appear higher than when measured directly in the full 
study population.29,30 Further, adherence rates also tend to 
increase when patients know that they are being monitored, 
ie, so-called “pleasing bias”.31
The retrospective SRQ method was used in this study 
because it may provide a more accurate indication of true 
patient level adherence, since patients’ answers concern 
actual, real-life drug intake and reduce the bias of patients 
being reminded to take medication merely by participating 
in the study. 
Patients in this study received the SRQs from and returned 
them to their treating physician, which may have increased 
adherence. This pleasing bias may also have made nonadher-
ent patients less willing to participate in the study, thereby 
also influencing the patient-reported adherence rate that 
corresponds with rates seen previously.4,24–27
The potential risk of overestimating patient adherence 
with this method was analyzed by taking both a conservative 
and a less conservative (sensitivity) approach to the data in 
this study. The conservative analysis may have overestimated 
mean patient adherence because it excluded data where PPI 
intake on an NSAID day was uncertain. On the other hand, the 
less conservative approach may have underestimated mean 
patient adherence. However, the less conservative approach 
is supported by the patients’ responses regarding long-term 
PPI intake patterns.
Although patients in this study were asked in the SRQ 
to state their drug intake for the previous 7 days, they still 
may have incorrectly recalled the drugs that they took over 
this short period. Further, the low number of patients in this 
study makes generalization of the results difficult because 
even a few patients may have had a large impact on overall 
adherence rates. Nevertheless, the adherence rates reported 
here are very similar to previous studies in general and within 
the same field.24–27
The results indicate that there is a “gastroprotection gap” 
in approximately 20%–30% of NSAID-treated patients with 
OA, RA, or AS who are at risk of adverse upper gastrointes-
tinal events. Estimates of the elevated risk of upper gastro-
intestinal events range from 1.8-fold to 4.0-fold in patients 
with inadequate gastroprotective agent protection or poor 
PPI adherence.20,24,27,32 Moreover, for every 10% decrease in 
adherence to PPI, the risk of upper gastrointestinal bleeding/
ulcers and upper gastrointestinal bleeding alone increases by 
9% and 6%, respectively.27 Similar results were shown in 
other studies.19,26 Since the risk of gastrointestinal events and 
death in nonadherent patients is increased and also associated 
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Figure 3 Distribution of patients with a reported adherence to PPis 80% using 
the conservative approach.
Abbreviation: PPi, proton pump inhibitor.Patient Preference and Adherence 2014:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1616
henriksson et al
with a societal economic burden,12,18–20 further studies on how 
to alleviate the problem of poor adherence to coprescribed 
PPI gastroprotective therapy in this vulnerable population 
of patients are needed.
Conclusion
In this study, the mean patient-reported adherence to 
coprescribed PPI in patients with OA, RA, or AS who were 
instructed to take PPIs on the same day as taking NSAIDs for 
gastroprotection was estimated to be 73%–81%. The level of 
patient adherence to PPI therapy in this group corresponds 
to that seen previously in registry studies, and indicates that 
there is still room for improvement in patient adherence to 
PPIs when used for the prevention of NSAID-associated 
upper gastrointestinal ulcers.
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